Share:
Professor Jo Neill and Parminder Singh bring psychopharmacology and IP protection & licensing expertise to a company pursuing psilocybin-based therapies
VANCOUVER, BC, May 25, 2021 /CNW/ - Albert Labs, an innovative developer of psychedelics-based therapeutics addressing urgent and unmet mental health indications through Real World Evidence (RWE) studies in the UK and across Europe, is pleased to announce the chairs of its Clinical and Scientific Advisory Boards. The company welcomes Professor Jo Neill as the Chair of Albert Labs Clinical Advisory Board and Parminder Singh Chair of its Scientific Advisory Board. We are delighted to have such authority with Jo and Parminder, they bring a wealth of knowledge and expertise in each of their disciplines and we look forward to working with them in driving our Clinical and Scientific Advisory boards said Graeme McFarlane, Chief Commercial Officer of Albert Labs.
Adding to their Expert Team, Albert Labs Announces the Formation and Chairs of its Two Advisory Boards
newswire.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newswire.ca Daily Mail and Mail on Sunday newspapers.
Drug developer uses RWE to research psychedelic therapies The UK-based development and research firm hopes to accelerate patient access to psychedelic therapies for treatment of various mental health conditions.
The pharmaceutical treatment options for patients suffering from mental illnesses are broader than ever before. Still, some patients are dealing with treatment-resistant ailments, and other patients are diagnosed with conditions that have few or no treatment options at all.
Albert Labs aims to offer hope to patients looking for relief for their mental health struggles. The company is using real-world evidence studies to help patients suffering from a range of mental-health challenges gain access to MDMA, psilocybin, psilocin and other psychedelics. Outsourcing-Pharma recently spoke with Albert Labs chief medical officer Malcolm Barratt-Johnson a 22-year industry vet who’s worked for AstraZeneca, Roche and other leading organizations about the
Microdose Psychedelic Insights: April Psychedelic Capital Investigates Clinical Trials & Real World Evidence & Going Mainstream: Mass Adoption
Clinical Trials & RWE and
1:30 PM: Intro
1:45 PM: BETTERLIFE PHARMA INC. (CSE: BETR) Featuring Patrick Kroupa, Ahmad Doroudian, Justin Kirkland
2:15 PM: Clinical Trials & RWE
Featuring Henri Sant-Cassia, Malcolm Barratt-Johnson, Matthew W. Johnson
2:45 PM: NanoPsy
3:15 PM: Going Mainstream: Mass Adoption Featuring Richard Skaife, Ronan Levy, Kathryn Tucker, Dustin Robinson
3:45 PM PharmAla Biotech Featuring Nicholas Kadysh & Justin Ling While PharmAla Biotech has a great team behind it, we re a relatively new company. I m excited to bring our story to the PsyCap audience, and to talk with Justin Ling about what I see as the future of the industry. - Nicholas Kadysh, President, PharmAla Biotech
NA Proactive news snapshot: Pacton Gold, Todos Medical, Chesapeake Financial, PlantX Life UPDATE …
A glance at some of the day s highlights from the Proactive Investors US and Canada newswires Your daily round-up from the world of Proactive
Pacton Gold Inc (CVE:PAC) (OTCPINK:PACXF) has sold the remaining 25% interest it holds in three properties in the Western Pilbara. The company has struck an asset sale agreement with Pilbara Gold Corporation Pty Ltd (PGC) and Raiden Resources (in which Pacton holds shares), whereby PGC will buy 25% of the Arrow, Yandicoogina and Boodalyerrie gold properties.
Todos Medical Ltd (OTCQB:TOMDF) has acquired Provista Diagnostics Inc, a US-based medical diagnostics that owns the intellectual property rights to proprietary breast cancer blood test Videssa and has a diagnostic lab currently performing coronavirus (COVID-19) PCR testing. Under the terms of the agreement, Todos said it has acquired Provista from its private equity owner f
vimarsana © 2020. All Rights Reserved.